白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2010年
4期
230-233
,共4页
白血病%基因%基因沉默%甲基化%治疗结果
白血病%基因%基因沉默%甲基化%治療結果
백혈병%기인%기인침묵%갑기화%치료결과
Leukemia%Genes%Gene silencing%Methylation%Treatment outcome
目的 研究INK4系列抑癌基因纯合子缺失、甲基化与白血病预后的关系.方法 采用聚合酶链反应(PCR)研究p16基因家族在白血病中纯合子缺失,应用甲基化敏感限制内切酶HpaⅡ结合PCR技术研究白血病患者p16、p15、p18、p19基因甲基化状况,用单因素、多因素Logistic回归分析其基因失活与急性白血病(AL)预后的关系.结果 基因表达组治疗有效27例(84.38%),基因失活组治疗有效11例(28.95%),基因表达组治疗有效率明显高于基因失活组(P<0.001).单因素、多因素Logistic回归分析结果显示p16、p15基因失活化疗有效率明显低于基因表达组.结论 p16、p15基因失活可作为AL病程进展、复发、预后的指标之一.
目的 研究INK4繫列抑癌基因純閤子缺失、甲基化與白血病預後的關繫.方法 採用聚閤酶鏈反應(PCR)研究p16基因傢族在白血病中純閤子缺失,應用甲基化敏感限製內切酶HpaⅡ結閤PCR技術研究白血病患者p16、p15、p18、p19基因甲基化狀況,用單因素、多因素Logistic迴歸分析其基因失活與急性白血病(AL)預後的關繫.結果 基因錶達組治療有效27例(84.38%),基因失活組治療有效11例(28.95%),基因錶達組治療有效率明顯高于基因失活組(P<0.001).單因素、多因素Logistic迴歸分析結果顯示p16、p15基因失活化療有效率明顯低于基因錶達組.結論 p16、p15基因失活可作為AL病程進展、複髮、預後的指標之一.
목적 연구INK4계렬억암기인순합자결실、갑기화여백혈병예후적관계.방법 채용취합매련반응(PCR)연구p16기인가족재백혈병중순합자결실,응용갑기화민감한제내절매HpaⅡ결합PCR기술연구백혈병환자p16、p15、p18、p19기인갑기화상황,용단인소、다인소Logistic회귀분석기기인실활여급성백혈병(AL)예후적관계.결과 기인표체조치료유효27례(84.38%),기인실활조치료유효11례(28.95%),기인표체조치료유효솔명현고우기인실활조(P<0.001).단인소、다인소Logistic회귀분석결과현시p16、p15기인실활화료유효솔명현저우기인표체조.결론 p16、p15기인실활가작위AL병정진전、복발、예후적지표지일.
Objective To explore the correlation between the family of p16 gene inactivation and prognosis of leukemia, and then to clarify, the pathogenesis of leukemia, and monitor process of leukemia. Methods We used polymerase chain reaction(PCR) to study p16, p15, p18, p19 gene homozygous deletion,by using methylation-sensitive enzyme and PCR technology to investigate p16, p15, p18, p19 gene methylation in leukemia. Results The effective rate with p16 and p15 gene activiation was 27 cases (84.38 %), the effective rate with p16 and p15 gene inactiviation was 11 cases (28.95%), and the total effective rate with p16 and p15 gene activiation was higher than p16and p15 gene inactivation. In case to use single and multi factor Logistic regression, effective rate in cases with p16 and p15 gene inactiviation was lower than that with p16 and p15 gene activation. Conclusion It might be one of parameters for forcasting progression, relapse and prognosis in AL.